Geode Capital Management
DRUG

Geode Capital Management’s Bright Minds Biosciences DRUG Stock Holding History

Geode Capital Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.31M Buy
104,146
+15,430
+17% +$1.21M ﹤0.01% 2708
2026
Q1 		$6.47M Buy
88,716
+25,170
+40% +$2.03M ﹤0.01% 2616
2025
Q4 		$4.96M Buy
63,546
+5,647
+10% +$377K ﹤0.01% 2777
2025
Q3 		$3.51M Buy
57,899
+378
+0.7% +$14.7K ﹤0.01% 2953
2025
Q2 		$1.5M Buy
+57,521
New +$1.72M ﹤0.01% 3213

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management's DRUG Position: Q2 2026 in Review

Geode Capital Management increased its Bright Minds Biosciences (DRUG) stake by 17% in Q2 2026, buying an estimated $1.21M and bringing the position to 104,146 shares worth $7.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2708.

Geode Capital Management first reported a position in DRUG in Q2 2025 and has held it in 5 quarters since. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Geode Capital Management held 104,146 shares of Bright Minds Biosciences worth $7.31M as of Q2 2026.
  • Geode Capital Management bought 15,430 Bright Minds Biosciences shares in Q2 2026, an estimated $1.21M.
  • Bright Minds Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2708 holding.
  • Geode Capital Management first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.